Intra-Cellular Therapies Inc
NASDAQ:ITCI

  • LAST PRICE
    74.7000
  • TODAY'S CHANGE (%)
    -0.4100 (-0.5459%)
  • Bid / Lots
    66.4000/ 1
  • Ask / Lots
    77.3900/ 1
  • Open / Previous Close
    74.9500 / 75.1100
  • Day Range
    74.4600
    75.7200
  • 52 Week Range
    45.5000
    84.8900
  • Volume
    429,663

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
ITCI
Intra-Cellular Therapies Inc
7.9B
-86.6x
---
TEM
Tempus AI Inc
7.6B
-6.2x
---
ASND
Ascendis Pharma A/S
8.5B
-15.5x
---
HALO
Halozyme Therapeutics Inc
7.8B
24.2x
---
LEGN
Legend Biotech Corp
9.4B
-31.9x
---
RARE
Ultragenyx Pharmaceutical Inc
5.4B
-7.9x
---
As of 2024-09-18

Company Information

Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.

Contact Information

Headquarters
430 East 29th Street, Suite 900NEW YORK, NY, United States 10016
Phone
646-440-9333
Fax
302-655-5049

Executives

Chairman of the Board, Chief Executive Officer
Sharon Mates
President
Michael Halstead
Chief Financial Officer, Executive Vice President
Sanjeev Narula
Executive Vice President, Chief Medical Officer
Suresh Durgam
Executive Vice President, Chief Commercial Officer
Mark Neumann

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$7.9B
Revenue (TTM)
$564.5M
Shares Outstanding
105.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.00
EPS
$-0.86
Book Value
$6.14
P/E Ratio
-86.6x
Price/Sales (TTM)
14.1
Price/Cash Flow (TTM)
---
Operating Margin
-19.93%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.